Novartis AG vs Smith & Nephew plc — how do they compare? Novartis AG trades at $152.33 (market cap $295.37B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Novartis AG is far larger — about 23.6× Smith & Nephew plc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | SNN | |
|---|---|---|
Market Cap | $295.37B | $12.54B |
Sector | Health | Health |
52-Week High | $168.62 | $38.70 |
52-Week Low | $119.31 | $28.73 |
Enterprise Value | $336.69B | $15.57B |
Dividend Yield | 3.07% | 2.65% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →